EVT0185
EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC) [1].
Product Specifications
CAS Number
2588489-03-4
UNSPSC
12352100
Target
ATP Citrate Lyase
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C(C)(C)CCCCC1=CC=C(CCCCC(C)(C(O)=O)C)C=C1
Molecular Formula
C22H34O4
Molecular Weight
362.50
References & Citations
[1]Gautam J, et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. Nature. 2025 Jul 30.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FUBI, Recombinant, Human (Ubiquitin-like Protein Finkel-Biskis-Reilly Murine Sarcoma Virus, MNSF beta, 40S Ribosomal Protein S30, asr1, FAU, Fub1, RPS30, S30) discontinued
Anti-SPIDR Antibody Picoband® Fluoro594 Conjugated
N- (6-Methoxy-3,4-dihydro-2H-1-benzopyran-4-ylidene) hydroxylamine